A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Potassium cation
Alphacetylmethadol
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Alphacetylmethadol.
Potassium cation
Cloxazolam
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Cloxazolam.
Potassium cation
Dihydrocodeine
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Dihydrocodeine.
Potassium cation
Drotebanol
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Drotebanol.
Potassium cation
Ethyl loflazepate
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Ethyl loflazepate.
Potassium cation
Flunitrazepam
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Flunitrazepam.
Potassium cation
Carfentanil
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Carfentanil.
Potassium cation
Chlorhexadol
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Chlorhexadol.
Potassium cation
Desomorphine
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Desomorphine.
Potassium cation
Dextromoramide
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Dextromoramide.
Potassium cation
Delorazepam
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Delorazepam.
Potassium cation
Tenamfetamine
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Tenamfetamine.
Potassium cation
Difenoxin
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Difenoxin.
Potassium cation
Etorphine
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Etorphine.
Potassium cation
Dichloralphenazone
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Dichloralphenazone.
Potassium cation
Camazepam
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Camazepam.
Potassium cation
Dimethyltryptamine
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Dimethyltryptamine.
Potassium cation
4-Bromo-2,5-dimethoxyamphetamine
The risk or severity of adverse effects can be increased when Cannabidiol is combined with 4-Bromo-2,5-dimethoxyamphetamine.
Potassium cation
Barbital
The risk or severity of adverse effects can be increased when Cannabidiol is combined with Barbital.
Potassium cation
4-Methoxyamphetamine
The risk or severity of adverse effects can be increased when Cannabidiol is combined with 4-Methoxyamphetamine.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3